Evidence map›Paper›PMID 38602045›Full record

ArticleInternational journal of cancer2024

Field experience with the 8-HPV-type oncoprotein test for cervical cancer screening among HPV-positive women living with and without HIV in LMICs.

Laura Downham, Mary Luz Rol, Mathilde Forestier, Pilar Romero, Laura Mendoza, Pamela Mongelós, María Alejandra Picconi, María Celeste Colucci, Valeria Mariel Padin, Ana Paula Flores and 23 more

Abstract readMulticenter Study
In one paragraph

Article in International journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Laura DownhamEarly Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France.ORCID 0009-0001-1669-6298
Mary Luz RolEarly Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France.
Mathilde ForestierEarly Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France.
Pilar RomeroInstituto Nacional de Cancerología, Bogota, Colombia.
Laura MendozaInstituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción, San Lorenzo, Paraguay.
Pamela MongelósInstituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción, San Lorenzo, Paraguay.
María Alejandra PicconiInstituto Nacional de Enfermedades Infecciosas-ANLIS Dr Malbrán, Buenos Aires, Argentina.
María Celeste ColucciInstituto Nacional de Enfermedades Infecciosas-ANLIS Dr Malbrán, Buenos Aires, Argentina.
Valeria Mariel PadinInstituto Nacional de Enfermedades Infecciosas-ANLIS Dr Malbrán, Buenos Aires, Argentina.
Ana Paula FloresAgencia Costarricense de Investigaciones Biomédicas (ACIB), Fundación Inciensa, Guanacaste, Costa Rica.
Michael ZúñigaAgencia Costarricense de Investigaciones Biomédicas (ACIB), Fundación Inciensa, Guanacaste, Costa Rica.
Annabelle FerreraInstituto de Investigaciones en Microbiología, Escuela de Microbiología, Universidad Nacional Autónoma de Honduras, Tegucigalpa, Honduras.
Yessy CabreraInstituto de Investigaciones en Microbiología, Escuela de Microbiología, Universidad Nacional Autónoma de Honduras, Tegucigalpa, Honduras.
Marcela Farfan CrispínFacultad de Medicina, Universidad Mayor, Real y Pontificia de San Francisco Xavier de Chuquisaca, Sucre, Bolivia.
Arianis Tatiana RamirezEarly Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France.
Londiwe CeleUniversity of Kwazulu Natal, Durban, South Africa.
Halimatou Diop-NdiayeLaboratoire Bactériologie-Virologie, CHU Aristide le Dantec, Dakar, Senegal.
Dianke SamatéLaboratoire Bactériologie-Virologie, CHU Aristide le Dantec, Dakar, Senegal.
Pascaline MangaLaboratoire Bactériologie-Virologie, CHU Aristide le Dantec, Dakar, Senegal.
Fadimatou Bintou ThiamLaboratoire Bactériologie-Virologie, CHU Aristide le Dantec, Dakar, Senegal.
Maria Isabel RodriguezInstituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción, San Lorenzo, Paraguay.
Jyoshma P DSouzaEarly Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France.
Victoria Nyawira NyagaDepartment of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium.
Mamadou DiopLaboratoire Bactériologie-Virologie, CHU Aristide le Dantec, Dakar, Senegal.
Motshedisi SebitloaneUniversity of Kwazulu Natal, Durban, South Africa.
Gloria Inés SánchezGrupo Infección y Cáncer, Universidad de Antioquia, Medellin, Colombia.
Carolina TeranFacultad de Medicina, Universidad Mayor, Real y Pontificia de San Francisco Xavier de Chuquisaca, Sucre, Bolivia.
Alejandro CalderonCaja Costarricense del Seguro Social, Puntarenas, Costa Rica.
Carolina WiesnerInstituto Nacional de Cancerología, Bogota, Colombia.
Raul MurilloEarly Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France.
Rolando HerreroEarly Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France.
Armando BaenaEarly Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0001-8717-6911
Maribel AlmonteEarly Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France.

Funding

Development and clinical validation of a multi-type HPV E6/E7 oncoprotein test for cervical cancer screening and triage in low- and middle-income countriesUH3CA202730 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI ALMONTE, MARIBEL · 2019 to 2021
$2.8M
Development and clinical validation of a multi-type HPV E6/E7 oncoprotein test for cervical cancer screening and triage in low- and middle-income countriesUH2CA202730 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI HERRERO, ROLANDO · 2016 to 2017
$974k
Centre International de Recherche sur le CancerHRP (the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human ProductionNCI NIH HHS UH2/3 CA202730NCI NIH HHS UH2 CA202730NCI NIH HHS UH3 CA202730World Health Organization 001
6 · The paper itself

Abstract

Overexpression of HPV-oncoproteins E6 and E7 is necessary for HPV-driven cervical carcinogenesis. Hence, these oncoproteins are promising disease-specific biomarkers. We assessed the technical and operational characteristics of the 8-HPV-type OncoE6/E7 Cervical Test in different laboratories using cervical samples from HPV-positive women living with (WLWH) and without HIV. The 8-HPV-type OncoE6/E7 Test (for short: "OncoE6/E7 test") was performed in 2833 HIV-negative women and 241 WLWH attending multicentric studies in Latin America (ESTAMPA study), and in Africa (CESTA study). Oncoprotein positivity were evaluated at each testing site, according to HIV status as well as type-specific agreement with HPV-DNA results. A feedback questionnaire was given to the operators performing the oncoprotein test to evaluate their impression and acceptability regarding the test. The OncoE6/E7 test revealed a high positivity rate heterogeneity across all testing sites (I

Indexed as

Early Detection of CancerHIV InfectionsPapillomavirus InfectionsUterine Cervical NeoplasmsAdultAfricaDeveloping CountriesDNA, ViralFemaleHumansLatin AmericaMiddle AgedOncogene Proteins, ViralPapillomaviridaeDNA, ViralOncogene Proteins, Viralcervical cancerfield experienceoncoproteins E6/E7women‐living with HIV

Identifiers

PMID38602045
PMCPMC11226355

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.